Six-month Progression-free Response Seen With HuMax-CD4 For CTCL

COPENHAGEN (Reuters) - Danish biotechnology firm Genmab said on Wednesday its cancer drug HuMax-CD4 (fully human monoclonal anti-CD4 antibody) used to treat cutaneous T-cell lymphoma (CTCL) had achieved long lasting results in a phase II trial.

The company said cutaneous T-cell lymphoma patients had shown an average response duration of more than 6.6 months before disease progression.

"These phase II data show the potential to provide a benefit to patients at a variety of disease stages," said Genmab Chief Executive Lisa N. Drakeman.

MeSH Headings: Clinical Trials : Environment and Public Health : Epidemiologic Methods : Evaluation Studies : Health : Health Occupations : Health Services Administration : Medicine : Investigative Techniques : Population Characteristics : Preventive Medicine : Public Health : Quality of Health Care : Specialties, Medical : Drugs, Investigational : Epidemiologic Study Characteristics : Clinical Trials, Phase II : Health Care Quality, Access, and Evaluation : Health Care Evaluation Mechanisms : Analytical, Diagnostic and Therapeutic Techniques and Equipment : Biological Sciences : Health Care

Copyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Back to news